Eosinophils in Chronic Urticaria: Supporting or Leading Actors?

Riccardo Asero, MD, 1 Massimo Cugno, MD, 2 and Alberto Tedeschi, MD 3

Abstract: Although their number may be increased in skin lesions, eosinophils have been rather neglected as possible participants to the pathogenesis of chronic urticaria because of the absence of peripheral eosinophilia in patients with this disease. However, recent data suggest a potentially relevant role played by activated eosinophils both in triggering the tissue factor pathway of coagulation cascade and as a source of vascular endothelial growth factor. Such phenomena seem more pronounced in patients showing a more severe disease. The present study will rediscuss the potential role of this cell line in chronic urticaria in the light of these recent observations.

Key Words: chronic urticaria, mastcells, eosinophils, VEGF, tissue factor

(WAO Journal 2009; 2:213–217)

INTRODUCTION

Chronic urticaria (CU), defined as the occurrence of spontaneous wheals, with or without angioedema, for more than 6 weeks is a rather frequent disorder. As in most other types of urticaria, the pathophysiologic basis of CU is unquestionably the recurrent degranulation of dermal mast cells and of basophils. Mast cells and, to a lesser extent, basophils, are generally regarded as the main effectors of this disease. However, the events occurring upstream and eventually resulting in histamine release from these cells are partially defined. Studies carried out during the last 2 decades have led to the detection of functional autoantibodies to the high affinity IgE receptor, FceRI, or to IgE that are able to cause degranulation and histamine release from both mast cells and basophils. 1–4 Complement plays a relevant role in this process by enhancing histamine release induced by FceRI autoantibodies. 5,6 However, it is generally agreed that autoantibodies to FceRI or to IgE can be detected in less than 50% of CU patients. Furthermore, there is increasing evidence that autoantibodies and in vivo autoreactivity can also be detected in other conditions and in healthy subjects. 7–10 All this means that the factors triggering histamine release in chronic urticaria remain a mystery in many cases. The reported efficacy of omalizumab in patients with refractory CU either with or without detectable autoantibodies11–15 and the observed, although not totally specific, inhibitory effect of heparin on autoantibody-triggered histamine release from basophils in vitro,16,17 suggest a common final pathway in histamine release, irrespective of the histamine-releasing factor involved.

HISTOLOGY OF CU

It is generally accepted that the histologic picture is more or less the same in all patients with CU irrespective of the presence or absence of autoantibodies. A perivascular infiltrate of CD4+ lymphocytes is always present.18 Infiltrating cells have the characteristics of both Th1 and Th2 cells; increased numbers of intradermal CD3, CD4, CD8-positive T cells have been detected with a Th0 cytokine profile. Neutrophils and a variable degree of eosinophils are also present.19,20 Eosinophils are often activated, particularly in patients without autoantibodies,20 and major basic protein can be measured in urticaria lesion even when eosinophils are not detected.21 The number of mast cells has been reported as increased in urticaria lesions19 although this finding has not been confirmed by more recent studies,19,22 and some basophil infiltration is also observed. It has been suggested that the infiltrate is similar to that of an allergy late-phase reaction.23,24

Interestingly, the eosinophil-derived major basic protein has been identified in autologous serum skin test site biopsies, along with eosinophil infiltration.25 The immune mechanisms and the main effector cells involved in chronic urticaria are shown in Figure 1.

WHO ACTIVATES MAST CELLS WHEN AUTOANTIBODIES ARE NOT PRESENT?

During the last 5 years, our group has spent some time and effort trying to respond to this question by measuring the circulating levels of some mediators potentially able to induce mast-cell degranulation and histamine release. In view of the constant absence of blood eosinophilia in CU, we measured serum levels of some substances not specifically related with eosinophils, namely stem cell factor,26 substance P,27 and interleukin (IL)-18.28 However, the concentration of

From the 1Allergy Unit, Clinica San Carlo, Paderno Dugnano (Milan), Italy; 2Department of Internal Medicine, University of Milan and IRCCS Foundation Maggiore Hospital, Mangiagalli and Regina Elena, Milan, Italy; and 3Allergy and Clinical Immunology Unit, IRCCS Foundation Maggiore Hospital, Mangiagalli and Regina Elena, Milan, Italy.

Correspondence to: Riccardo Asero, MD, Ambulatorio di Allergologia, Clinica San Carlo, Via Ospedale 21, 20037 Paderno Dugnano (MI), Italy. Telephone: +39-02-99038470. Fax: +39-02-99038223. E-mail: r.asero@libero.it.

Copyright © 2009 by World Allergy Organization
these mediators did not significantly differ between patients and controls. Recently, we have been luckier when, based on the observation of a higher prevalence of positive autologous plasma skin test over autologous serum skin test, we started looking at the coagulation cascade and were able to demonstrate that CU is characterized by thrombin generation, which is the result of an activation of the tissue pathway of blood coagulation. Notably, studies in animal models have shown that thrombin is able to induce mast cell degranulation, and in rat mast cell populations, the response to thrombin is equipotent with FcεRI-mediated activation. Thus (although evidence that thrombin induces mast cell degranulation in humans is still missing), thrombin might be a candidate mast-cell activating factor, at least in patients whose sera don’t contain autoantibodies and show an activation of coagulation cascade. One good question is if thrombin activates all mast cells, why do we see just skin mast cell activation in CU? In other words, why is there skin selectivity in CU? In effect, there are studies showing that in CU patients there is bronchial hyper-responsiveness and, sometimes, frank asthma.

FIGURE 1. Immune mechanisms and main effector cells involved in chronic urticaria. A, Mast cells are activated either by autoantibodies to FcεRI or IgE and/or by other histamine releasing factors and release several mediators (histamine, leukotrienes, VEGF) that concur to produce the marked vasodilation that stands at the basis of both wheal-and flare reaction and angioedema. Some mediators and chemokines released by mast cells can recruit and activate eosinophils that in turn release inflammatory mediators and produce tissue factor, the main initiator of the extrinsic pathway of the coagulation cascade. The major basic protein released by eosinophils can induce mast cell degranulation. B, Eosinophils can be activated either directly by autoantibodies against the low affinity IgE receptor or indirectly by mast-cell derived mediators. C, Activated T-cells can induce mast cell degranulation by cell-to-cell contact. This process leads to the formation and release of cytokines such as TNF-α that has the capacity to induce gene expression in mast cells by an autocrine mechanism. ECP, eosinophil cationic protein; GM-CSF, granulocyte-monocyte colony-stimulating factor; MBP, major basic protein; PAF, platelet-activating factor; SCF, stem cell factor.

EOSINOPHILS AS ACTIVATORS OF THE COAGULATION CASCADE AND AS SOURCE OF VEGF IN CHRONIC URTICARIA (FIG. 2)

Interestingly, although the role of other cells cannot be ruled out, investigating further the activation of the coagulation cascade, we found that the cells expressing tissue factor in chronic urticaria, and hence triggering the activation of the extrinsic pathway, are eosinophils. In fact, immunohistochemical experiments showed that tissue factor colocalized with eosinophil cationic protein, a classic cell marker of eosinophils. These findings highlight the importance of eosinophils in chronic urticaria as a source of tissue factor, in keeping with recent studies showing that eosinophils store tissue factor and rapidly transfer it to the cell membrane during activation. The strong expression of tissue factor in
chronic urticaria lesional skin may be because of eosinophil activation, even if patients with chronic urticaria do not show peripheral eosinophilia, probably because tissue factor facilitates the early transendothelial migration of the eosinophils. It is interesting to note that eosinophils in chronic urticaria may be activated both by direct and indirect mechanisms. In a single, hitherto unconfirmed, study autoantibodies directed against CD23, the low-affinity IgE receptor located on eosinophil membrane, have been detected in about 65% of chronic urticaria patients. These autoantibodies can activate eosinophils inducing the release of major basic protein, which in turn causes mast cell degranulation. In addition, eosinophil involvement might be secondary to the mast cell activation caused by anti-FceRI and anti-IgE autoantibodies or other histamine-releasing factors. It has been demonstrated that several mediators and cytokines released by activated mast cells can recruit and stimulate eosinophils. Among others, mast cells represent an important source of IL-5, tumor necrosis factor (TNF)-α, platelet-activating factor and eotaxin, molecules that can exert potent chemotactic and stimulating activities on eosinophils.

One further recent observation is that patients with CU show a significant increase of vascular endothelial growth factor (VEGF). VEGF is the most potent regulator of angiogenesis presently known, and one of the major mediators of vascular permeability; furthermore, it exerts a vaso-dilator effect through an increase of nitric oxide production by endothelial cells. Notably, eosinophils are the main source of VEGF in CU as well, in agreement with the in vitro observations that human peripheral blood eosinophils have the capacity to induce angiogenesis. All these findings clearly suggest that eosinophils might play a role in chronic urticaria.

**WHO IS ACTIVATING WHOM?**

As reviewed above, it seems rather clear that both mast cells and eosinophils are activated in CU. Who is the one that starts all the process? Is eosinophil activation the result of mast cell-derived mediators release or are eosinophils themselves the cause of mast cell activation and subsequent histamine release?

It cannot be excluded that the leading actor may change in different subsets of patients. In patients showing circulating FceRI and anti-IgE autoantibodies it is very likely that the main actor is the mast cell whereas in other patients showing only anti-FceRII autoantibodies such role might be played by eosinophils. Finally, it cannot be excluded that T cells, which have been found in chronic urticaria lesional skin, also play a relevant role, possibly by activating the mast cells via a cell-to-cell contact. In fact, it has been demonstrated that T cells can activate mast cells by cell-to-cell contact, thus

**FIGURE 2.** Activation of the extrinsic pathway of the coagulation cascade by eosinophil-derived tissue factor in patients with chronic urticaria. Eosinophils produce and store tissue factor (blue triangles), and rapidly transfer it to the cell membrane during activation. Activation of the coagulation cascade and fibrinolysis in patients with chronic urticaria is demonstrated by the increased plasma levels of the prothrombin fragment F1+2 and D-dimer (indicated by red arrows).
proving the release of cytokines and inflammatory mediators such as histamine, TNF-α and matrix metalloproteinase-9. Furthermore, an aberrant signaling through the p21Ras pathway has been found in peripheral blood mononuclear cells of patients with chronic urticaria, a finding that is in agreement with lymphocyte activation and supports the autoimmune basis of the disease. Finally, the clinical response of chronic urticaria to corticosteroid treatment suggests to the importance of the cellular infiltrate (T cells, eosinophils, or even basophils) because mast cells tend to be steroid-resistant.

REFERENCES

1. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin Exp Allergy. 1991;21:695–704.

2. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599–1604.

3. Fiebiger E, Maurer D, Holub H, Reingering B, Hartmann G, et al. Serum IgG autoantibodies directed against the alpha chain of FceRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest. 1995;96:2606–2612.

4. Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcεRI a (subunit). J Allergy Clin Immunol. 1998;101:672–676.

5. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol. 1999;104:169–172.

6. Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgE-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol. 2002;109:114–118.

7. Mari A. Allergy-like asthma and rhinitis. A cross-sectional survey of a respiratory cohort and a diagnostic approach using the autologous serum skin test. Int Arch Allergy Immunol. 2004;133:29–39.

8. Guttman-Yassky E, Bergman R, Maor C, Mamorsky M, Pollack S, Shahar E. The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals. J Eur Acad Dermatol Venereol. 2007;21:35–39.

9. Eckman JA, Hamilton RG, Saini SS. Independent evaluation of a marker and pathogenetic factor for a distinct subset of chronic urticaria patients. J Invest Dermatol. 1999;103:1105–1110.

10. Tedeschi A, Lorini M, Asero R. Plasma of chronic urticaria patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120:979–981.

11. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic urticaria and non-allergic asthma: a common mechanism? J Invest Allergol Clin Immunol. 2007;41:56–59.

12. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma levels of IgE and eosinophil granule major basic protein in chronic urticaria. J Allergy Clin Immunol. 1999;103:484–493.

13. Peters M, Schroeter A, Kephard G, Gleich G. Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol. 1983;81:39–43.

14. Sheikh J. Effect of omalizumab on patients with chronic urticaria: issues with and without anti-FcεRI or anti-IgE autoantibodies. J Allergy Clin Immunol. 1999;103:484–493.

15. Dreyfus DH. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol. 2008;100:88–89.

16. Fiebiger E, Maurer D, Holub H, Reingering B, Hartmann G, et al. Serum IgG autoantibodies directed against the alpha chain of FceRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest. 1995;96:2606–2612.

17. Faggiolo U, Cancian M, Bertollo L, Peserico A, Amadori A. Inhibitory effect of heparin on skin reactivity to autologous serum in chronic urticaria. Venereol Leprol. 2008;74:157–158.

18. Grattan CE, Winkelmann RK, Leiferman KM. Eosinophil major basic protein in autologous serum and saline skin tests in chronic idiopathic urticaria. Br J Dermatol. 1997;136:132–148.

19. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109:694–700.

20. Sahu G, Lu, Poon E, Orchard G, Lane D, Francis D, et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Allergy Clin Immunol. 1999;103:484–493.

21. Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, et al. Eosinophils are a major intravascular location for tissue factor expression in patients with chronic urticaria. Int Arch Allergy Immunol. 2004;133:271–281.

22. Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, et al. Eosinophils are a major intravascular location for tissue factor expression in patients with chronic urticaria. Int Arch Allergy Immunol. 2004;133:271–281.

23. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of chronic urticaria patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120:979–981.

24. Tedeschi A, Lorini M, Asero R. Plasma level interleukin-18 in patients with chronic urticaria. J Allergy Clin Immunol. 2007;120:979–981.

25. Tedeschi A, Lorini M, Suli C, Asero R. Serum interleukin-18 in patients with chronic urticaria: association with disease activity. Clin Exp Dermatol. 2005;30:171–175.

26. Asero R, Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Invest Allergol Clin Immunol. 2006;16:19–23.

27. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Invest Allergol Clin Immunol. 2006;16:19–23.

28. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma levels of IgE and eosinophil granule major basic protein in chronic urticaria. Eur Ann Allergy Clin Immunol. 2005;37:358–363.

29. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Investig Allergol Clin Immunol. 2008;19:204.

30. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Investig Allergol Clin Immunol. 2008;19:204.

31. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Investig Allergol Clin Immunol. 2008;19:204.

32. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Investig Allergol Clin Immunol. 2008;19:204.

33. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Investig Allergol Clin Immunol. 2008;19:204.

34. Tedeschi A, Lorini M, Asero R. Simultaneous occurrence of chronic autoimmunee urticaria and non-allergic asthma: a common mechanism? J Investig Allergol Clin Immunol. 2008;19:204.
growth factor (VEGF) in patients with chronic urticaria 2009 May 27. [Epub ahead of print].

42. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development.* 1992;114:521–532.

43. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol.* 1995;146:1029–1039.

44. Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F. Human peripheral blood eosinophils induce angiogenesis. *Int J Biochem J Biol.* 2005;37:628–636.

45. Bhattacharyya SP, Drucker I, Reshef T, Kirshenbaum AS, Metcalfe DD, Mekori YA. Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact. *J Leukoc Biol.* 1998;63:337–341.

46. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. *J Immunol.* 2001;167:4008–4016.

47. Confino-Cohen R, Aharoni D, Goldberg A, Gurevitch I, et al. Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria. *J Allergy Clin Immunol.* 2002;109:349–356.